420 related articles for article (PubMed ID: 19951971)
1. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia.
Park S; Chapuis N; Tamburini J; Bardet V; Cornillet-Lefebvre P; Willems L; Green A; Mayeux P; Lacombe C; Bouscary D
Haematologica; 2010 May; 95(5):819-28. PubMed ID: 19951971
[TBL] [Abstract][Full Text] [Related]
2. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody.
Chapuis N; Tamburini J; Cornillet-Lefebvre P; Gillot L; Bardet V; Willems L; Park S; Green AS; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
Haematologica; 2010 Mar; 95(3):415-23. PubMed ID: 20007139
[TBL] [Abstract][Full Text] [Related]
3. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.
Tamburini J; Chapuis N; Bardet V; Park S; Sujobert P; Willems L; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
Blood; 2008 Jan; 111(1):379-82. PubMed ID: 17878402
[TBL] [Abstract][Full Text] [Related]
4. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
Sandhöfer N; Metzeler KH; Rothenberg M; Herold T; Tiedt S; Groiß V; Carlet M; Walter G; Hinrichsen T; Wachter O; Grunert M; Schneider S; Subklewe M; Dufour A; Fröhling S; Klein HG; Hiddemann W; Jeremias I; Spiekermann K
Leukemia; 2015 Apr; 29(4):828-38. PubMed ID: 25322685
[TBL] [Abstract][Full Text] [Related]
5. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
[TBL] [Abstract][Full Text] [Related]
6. Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML.
Herschbein L; Liesveld JL
Blood Rev; 2018 May; 32(3):235-248. PubMed ID: 29276026
[TBL] [Abstract][Full Text] [Related]
7. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
Martelli AM; Evangelisti C; Chiarini F; McCubrey JA
Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809
[TBL] [Abstract][Full Text] [Related]
8. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.
Martelli AM; Evangelisti C; Chiarini F; Grimaldi C; Manzoli L; McCubrey JA
Expert Opin Investig Drugs; 2009 Sep; 18(9):1333-49. PubMed ID: 19678801
[TBL] [Abstract][Full Text] [Related]
9. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.
Park S; Chapuis N; Bardet V; Tamburini J; Gallay N; Willems L; Knight ZA; Shokat KM; Azar N; Viguié F; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
Leukemia; 2008 Sep; 22(9):1698-706. PubMed ID: 18548104
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.
Tabe Y; Tafuri A; Sekihara K; Yang H; Konopleva M
Expert Opin Ther Targets; 2017 Jul; 21(7):705-714. PubMed ID: 28537457
[TBL] [Abstract][Full Text] [Related]
11. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.
Martelli AM; Tazzari PL; Evangelisti C; Chiarini F; Blalock WL; Billi AM; Manzoli L; McCubrey JA; Cocco L
Curr Med Chem; 2007; 14(19):2009-23. PubMed ID: 17691943
[TBL] [Abstract][Full Text] [Related]
12. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
Burris HA
Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
[TBL] [Abstract][Full Text] [Related]
13. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.
Chiarini F; Lonetti A; Teti G; Orsini E; Bressanin D; Cappellini A; Ricci F; Tazzari PL; Ognibene A; Falconi M; Pagliaro P; Iacobucci I; Martinelli G; Amadori S; McCubrey JA; Martelli AM
Oncotarget; 2012 Dec; 3(12):1615-28. PubMed ID: 23271044
[TBL] [Abstract][Full Text] [Related]
14. The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells.
Brenner AK; Andersson Tvedt TH; Bruserud Ø
Molecules; 2016 Nov; 21(11):. PubMed ID: 27845732
[TBL] [Abstract][Full Text] [Related]
15. Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison.
Nepstad I; Hatfield KJ; Aasebø E; Hernandez-Valladares M; Brenner AK; Bartaula-Brevik S; Berven F; Selheim F; Skavland J; Gjertsen BT; Reikvam H; Bruserud Ø
Expert Opin Ther Targets; 2018 Jul; 22(7):639-653. PubMed ID: 29889583
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D
Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625
[TBL] [Abstract][Full Text] [Related]
17. Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis.
Bertacchini J; Guida M; Accordi B; Mediani L; Martelli AM; Barozzi P; Petricoin E; Liotta L; Milani G; Giordan M; Luppi M; Forghieri F; De Pol A; Cocco L; Basso G; Marmiroli S
Leukemia; 2014 Nov; 28(11):2197-205. PubMed ID: 24699302
[TBL] [Abstract][Full Text] [Related]
18. Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism.
Nepstad I; Reikvam H; Brenner AK; Bruserud Ø; Hatfield KJ
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382066
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.
Weisberg E; Banerji L; Wright RD; Barrett R; Ray A; Moreno D; Catley L; Jiang J; Hall-Meyers E; Sauveur-Michel M; Stone R; Galinsky I; Fox E; Kung AL; Griffin JD
Blood; 2008 Apr; 111(7):3723-34. PubMed ID: 18184863
[TBL] [Abstract][Full Text] [Related]
20. The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells.
Nepstad I; Hatfield KJ; Grønningsæter IS; Reikvam H
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]